Cost effectiveness analysis of BRAF testing for low-risk papillary thyroid microcarcinomas
In conclusion, this study demonstrates the economic and clinical advantages of incorporating BRAF<sup>V600E</sup> genetic testing in the management of lrPTMCs. Our model supports further real-life studies of BRAF<sup>V600E</sup> testing for lrPTMCs.
Authors
- Idit Tessler (ORCID: https://orcid.org/0000-0002-3297-7022)
- Eran E. Alon (ORCID: https://orcid.org/0000-0002-2981-6092)
- Moshe Leshno (ORCID: https://orcid.org/0000-0003-1485-0623)
- Gilad Feinmesser
- Galit Avior (ORCID: https://orcid.org/0000-0002-6716-8671)
Institutions
- Tel Aviv University (IL)
- Technion – Israel Institute of Technology (IL)
- Sheba Medical Center (IL)
Publication Details
- Journal
- American Journal of Otolaryngology
- Published
- 2024-12-10
- DOI
- https://doi.org/10.1016/j.amjoto.2024.104559
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00